Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957832 | 0.81 | RAB9A (0.40) | HPGDSMN1; SMN2RAB9AHTTNPC1 | |
| SCHEMBL2957829 | 0.72 | GAA (0.41) | HPGDSMN1; SMN2RAB9AHTTKDM4E | |
| SCHEMBL16242373 | 0.69 | HPGD (0.34) | HPGDSMN1; SMN2RAB9AHTTKDM4E | |
| SCHEMBL25446918 | 0.65 | ALDH1A1 (0.58) | HPGDSMN1; SMN2RAB9AHTTNPC1 | |
| SCHEMBL13450341 | 0.65 | SMN1; SMN2 (0.61) | HPGDSMN1; SMN2HTTKDM4EACHE | |
| SCHEMBL1573944 | 0.64 | RAB9A (0.42) | HPGDSMN1; SMN2RAB9AHTTKDM4E | |
| SCHEMBL1574050 | 0.64 | GAA (0.42) | HPGDSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL21503581 | 0.62 | ACHE (0.58) | HPGDSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL13450334 | 0.62 | THRB (0.63) | SMN1; SMN2HTTTP53LMNAALDH1A1 | |
| SCHEMBL1691944 | 0.62 | HPGD (0.40) | HPGDSMN1; SMN2HTTNPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937648-B1 | DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI SA (FR) | 2014-11-26 | — | — | EP | disclosed |
| US-8357698-B2 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | SANOFI (FR) | 2013-01-22 | — | — | US | disclosed |
| US-20100286133-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | SANOFI-AVENTIS (FR) | 2010-11-11 | — | — | US | disclosed |
| US-7772268-B2 | inhibitors of hormone-sensitive lipase and/or endothelial lipase; for treatment of diabetes mellitus, dyslipidemia and atherosclerotic disorders | SANOFI-AVENTIS (FR) | 2010-08-10 | — | — | US | disclosed |
| US-20080287448-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| EP-1937648-A1 | DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042178-A1 | DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287448-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | PNLIP, DAGLA, MGLL | HPGD 785/4885SMN1; SMN2 4603/4885RAB9A 1832/4885 |
| US-20100286133-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | PNLIP, DAGLA, MGLL | HPGD 785/4885SMN1; SMN2 4603/4885RAB9A 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.